Quantum Biopharma Ltd. (NASDAQ:QNTM – Get Free Report) saw a large increase in short interest in May. As of May 29th, there was short interest totaling 411,604 shares, an increase of 85.7% from the May 14th total of 221,665 shares. Approximately 11.8% of the shares of the company are short sold. Based on an average trading volume of 620,229 shares, the days-to-cover ratio is currently 0.7 days.
Analysts Set New Price Targets
Several equities analysts recently issued reports on QNTM shares. Wall Street Zen cut Quantum Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings lowered shares of Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 28th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Quantum Biopharma has an average rating of “Sell”.
Get Our Latest Stock Report on Quantum Biopharma
Quantum Biopharma Trading Down 1.3%
Quantum Biopharma (NASDAQ:QNTM – Get Free Report) last posted its earnings results on Thursday, March 26th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.49).
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of QNTM. Virtu Financial LLC bought a new stake in shares of Quantum Biopharma during the fourth quarter valued at approximately $76,000. Jane Street Group LLC bought a new position in Quantum Biopharma in the 4th quarter worth approximately $80,000. Finally, Platform Technology Partners bought a new position in Quantum Biopharma in the 1st quarter worth approximately $199,000. Institutional investors own 1.24% of the company’s stock.
About Quantum Biopharma
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.
Featured Stories
- Five stocks we like better than Quantum Biopharma
- Healthcare Added 35,200 Jobs—3 Stocks Positioned to Benefit
- Mission Control: Floating In SpaceX’s Record-Breaking Orbit
- Forget AI for a Moment, This Homebuilder Is Stealing the Show
- Qualcomm Drops 25%, But Investor Day Could Reverse the Slide
Receive News & Ratings for Quantum Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
